Physician profile
Jason A Colinger
NPI 1609829241
$13,943.25
in general payments reported to CMS, 2019-2025
47 companies · $1,832 in 2025
The $1,832 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,310 · 2020: $1,552 · 2021: $2,470 · 2022: $2,308 · 2023: $2,551 · 2024: $1,920 · 2025: $1,832.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,302.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,775.25 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,351.96 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Lilly USA, LLC | $1,196.51 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $912.58 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $877.09 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $656.69 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Amarin Pharma, INC. | $635.24 | 2019-2023 | |
| Otsuka America Pharmaceutical, INC. | $568.33 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Esperion Therapeutics, INC. | $498.70 | 2020-2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $498.15 | 2019-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $452.58 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $450.87 | 2019-2025 | |
| Amgen INC. | $444.29 | 2019-2025 | Otezla, Repatha, Otezla |
| Lundbeck LLC | $380.10 | 2023-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $373.74 | 2019-2023 | Verquvo, Belsomra, Steglatro |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Colinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.